October is Breast Cancer Awareness Month, which each year calls attention to the condition that one in every eight women will face throughout their lifetimes. While the challenge of breast cancer remains, America’s biopharmaceutical companies have made substantial progress in recent decades toward finding effective treatments for the disease, providing hope for continued success in discovering new solutions.
According to the American Cancer Society, the impact of breast cancer is staggering. The group estimates that during 2018 alone, 266,120 new cases of invasive breast cancer will be diagnosed, making breast cancer the second most common form of cancer affecting women, behind only skin cancer. Additionally, it is predicted that 40,920 women will die from the disease, which translates to 112 deaths every day.
For patients like Jessica Baker, those numbers are personal. After her diagnosis of an aggressive form of Stage II Breast Cancer, she threw everything she had into the fight against the disease, motivated by her son and the thousands of other women fighting for another birthday, Christmas or summer vacation. Jessica, who also happens to be a biopharmaceutical researcher, knew the stakes were high, but that there was reason for hope. Six years later, that hope is even stronger, because of the progress we’ve made in our ability to better diagnose and treat breast cancer.